87488-61-7

Basic information

• Product Name: 2-Propen-1-one, 3-(dimethylamino)-1-(2-nitrophenyl)-
• CAS NO: 87488-61-7
• Molecular Formula: C11H12N2O3
• Molecular Weight: 220.228
• Mol File: 87488-61-7.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: 2-Propen-1-one, 3-(dimethylamino)-1-(2-nitrophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Propen-1-one, 3-(dimethylamino)-1-(2-nitrophenyl)-(87488-61-7)
• EPA Substance Registry System: 2-Propen-1-one, 3-(dimethylamino)-1-(2-nitrophenyl)-(87488-61-7)

Safety Data

• Hazardous Substances Data: 87488-61-7(Hazardous Substances Data)

Upstream product

• 577-59-3 2-acetylnitrobenzene 
• 68-12-2 N,N-dimethyl-formamide 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 67-63-0 isopropyl alcohol 
• 614-21-1 2-nitroacetophenone 

Downstream Products

• 111562-32-4 2-(1H-pyrazol-3-yl)aniline 
• 59844-05-2 3-(2-nitrophenyl)-1H-pyrazole 
• 35928-59-7 2,2-dibromo-1-(2-nitrophenyl)ethan-1-one 
• 172538-83-9 benzyl 4-oxoquinoline-1(4H)-carboxylate 
• 83-54-5 1-methyl-4-quinolone 
• 681827-50-9 benzyl 2-methyl-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING)

The present invention relates to compounds of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof that are useful as modulators of STING (Stimulator of Interferon Genes). The present invention further relates to the compounds of formula (I) for use as a medicament and to a pharmaceutical composition comprising said compounds.

Conjugate Addition Routes to 2-Alkyl-2,3-dihydroquinolin-4(1H)-ones and 2-Alkyl-4-hydroxy-1,2-dihydroquinoline-3-carboxylates

Under CuBr·SMe2/PPh3 catalysis (5/10 mol-%) RMgCl (R = Me, Et, nPr, CH=CH2, nBu, iBu, nC5H11, cC6H11, Bn, CH2Bn, nC11H23) readily (–78 °C) undergo 1,4-addition to Cbz or Boc protected quinolin-4(1H)-ones to provide 2-alkyl-2,3-dihydroquinolin-4(1H)-ones (14 examples, 54–99 % yield). Asymmetric versions require AlEt3 to Boc-protected ethyl 6-substituted 4(1H)-quinolone-3-carboxylates (6-R group = all halogens, n/i/t-alkyls, CF3) and provide 61–91 % yield, 30–86 % ee; any halogen, Me, or CF3 provide the highest stereoselectivities (76–86 % ee). Additions of AlMe3 or Al(nC8H17)3 provide ≈ 45 and ≈ 75 % ee on addition to the parent (6-R = H). Ligand (S)-(BINOL)P–N(CHPh2)(cC6H11) provides the highest ee values engendering addition to the Si face of the 4(1H)-quinolone-3-carboxylate. Allylation and deprotection of a representative 1,4-addition product example confirm the facial selectivity (X-ray crystallography).

Pyrimidine compounds

The present invention belongs to the field of pharmaceutical synthesis, and relates to pyrimidine compounds, a preparation method and applications thereof, a pharmaceutical composition containing the pyrimidine compounds as active components, and applications of the pyrimidine compounds in preparation of antitumor drugs. The present invention discloses a pyrimidine compound having a structure represented by a formula I, wherein W is NH, R1 is a nitrogen-containing five-membered heterocyclic ring, and R2 is a nitrogen-containing basic group. According to the present invention, the pyrimidine compound can inhibit a variety of tumor cells, can particularly and selectively act on EGFRL858R/T790M lung cancer cells, and can overcome the existing EGFR inhibitors, wherein the IC50 of the compounds is increased by 10-100 times compared to wild-type cells. The formula I is defined in the specification.